AFT-16 also explored neoadjuvant atezolizumab before concurrent chemoradiotherapy to a standard 60 Gy in 30 fractions, followed by adjuvant atezolizumab, and showed an 18-month OS of 84%. 32 While ...

Tremelimumab has been approved by the FDA in the US for use in tandem with AZ's PD-L1 inhibitor Imfinzi (durvalumab ... of PD-L1 inhibitor Tecentriq (atezolizumab) and CD20-targeting antibody ...

The study met its primary endpoint demonstrating a statistically significant and clinically meaningful improvement in EFS with the durvalumab regimen vs the placebo regimen. Topline results were ...